R&D Pipeline
Glenmark’s R&D is committed to identifying products that fulfill unique and unmet medical needs in inflammation disorders, especially in respiratory and dermatology therapies and also oncology.
Therapy | Molecule | Indication | MoA/Class |
Pre-Clinical | Phase 1 | Phase 2 a | Phase 2 b | Phase 3 | Approval |
Respiratory | Ryaltris™ - GSP 301 | Steroid + AH | Allergic Rhinitis |
Respiratory | GBR 310 | Biosimilar | Asthama,CIU |
Respiratory | GSP 304 | LAMA | COPD |
Immunology | GRC 39815 | ROR y t Inhibitor | COPD |